...
首页> 外文期刊>The Canadian journal of cardiology. >Loperamide Cardiac Toxicity: Pathophysiology, Presentation, and Management
【24h】

Loperamide Cardiac Toxicity: Pathophysiology, Presentation, and Management

机译:Loperamide Cardiac Toxicity: Pathophysiology, Presentation, and Management

获取原文
获取原文并翻译 | 示例
           

摘要

? 2022 Canadian Cardiovascular SocietyLoperamide is a nonprescription medication commonly used to treat diarrhea. Although it is an opioid, it is very poorly absorbed and well tolerated, with no systemic toxicity at standard doses. In recent years, however, loperamide has been ingested in very large quantities, sometimes with concomitant medications intended to enhance absorption and/or passage across the blood-brain barrier. Most people who misuse loperamide do so for its euphoric effects or to treat symptoms of opioid withdrawal. In addition to the risks of central opioid toxicity, this practice can result in potentially fatal cardiac dysrhythmias, because very high concentrations of loperamide alter the cardiac action potential. Patients will often present with recurrent, unexplained syncope accompanied with marked electrocardiographic abnormalities including QT-interval prolongation, widening of the QRS complex, and dysrhythmias such as torsades de pointes. Treatment involves early identification and discontinuation of loperamide, reversal of central opioid effects if present, and interventions aimed at addressing any cardiac conduction abnormalities. In addition, if there is an underlying opioid use disorder, efforts should be made to refer to specialised addictions care and initiate opioid agonist therapy when appropriate. We review the pharmacology of loperamide and the clinical presentation, pathophysiology, and suggested management of loperamide cardiac toxicity.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号